Ingrid Buchler, M.S. joined the Drug Discovery Division at the Lieber Institute in September 2011. Her current work involves applying medicinal chemistry principles and synthetic skills to elucidate potential target lead matter for drug discovery while supporting diverse programs simultaneously, i.e. ion channels, kinases and enzyme pathways. Prior to joining the Lieber Institute, Ingrid worked in Medicinal Chemistry for over 10 years in inflammation and pain management at Pfizer Global Research and Development and legacy Pharmacia Corp. Her contributions to the discovery of new chemical entities aided in the development of a Phase II clinical candidate for inflammation. During her tenure at Pfizer, Ingrid was co-recipient of the Pfizer Team Award for Excellence and the Pfizer Green Chemistry Award.
LIBD Speaker Series: Bryan W. Luikart, Ph.D.
Understanding the Neurobiological Basis of Autism Using PTEN as a Genetic Model Bryan W. Luikart, Ph.D. Assistant Professor Department of Molecular and Systems Biology Geisel School of Medicine at Dartmouth When: September 26 2:00pm-3:00pm Where: The Lieber Institute for Brain […]